Literature DB >> 17543337

Non-homologous recombination of deoxyribonucleoside kinases from human and Drosophila melanogaster yields human-like enzymes with novel activities.

Monica L Gerth1, Stefan Lutz.   

Abstract

In antiviral and cancer therapy, deoxyribonucleoside kinases (dNKs) are often the rate-limiting step in activating nucleoside analog (NA) prodrugs into their cytotoxic, phosphorylated forms. We have constructed libraries of hybrid enzymes by non-homologous recombination of the pyrimidine-specific human thymidine kinase 2 and the broad-specificity dNK from Drosophila melanogaster; their low sequence identity has precluded engineering by conventional, homology-dependent shuffling techniques. From these libraries, we identified chimeras that phosphorylate nucleoside analogs with higher activity than either parental enzyme, and that possess new activity towards the anti-HIV prodrug 2',3'-didehydro-3'-deoxythymidine (d4T). These results demonstrate the potential of non-homologous recombination within the dNK family for creating enzymes with new and improved activities towards nucleoside analogs. In addition, our results exposed a previously unknown role for the C-terminal regions of these dNKs in determining substrate selectivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543337      PMCID: PMC1986717          DOI: 10.1016/j.jmb.2007.05.021

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  33 in total

1.  A combinatorial approach to hybrid enzymes independent of DNA homology.

Authors:  M Ostermeier; J H Shim; S J Benkovic
Journal:  Nat Biotechnol       Date:  1999-12       Impact factor: 54.908

2.  Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.

Authors:  X Zheng; M Johansson; A Karlsson
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

3.  Enhanced crossover SCRATCHY: construction and high-throughput screening of a combinatorial library containing multiple non-homologous crossovers.

Authors:  Yasuaki Kawarasaki; Karl E Griswold; James D Stevenson; Tzvia Selzer; Stephen J Benkovic; Brent L Iverson; George Georgiou
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

4.  SWISS-MODEL: An automated protein homology-modeling server.

Authors:  Torsten Schwede; Jürgen Kopp; Nicolas Guex; Manuel C Peitsch
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

5.  Rapid generation of incremental truncation libraries for protein engineering using alpha-phosphothioate nucleotides.

Authors:  S Lutz; M Ostermeier; S J Benkovic
Journal:  Nucleic Acids Res       Date:  2001-02-15       Impact factor: 16.971

6.  Mutagenesis of non-conserved active site residues improves the activity and narrows the specificity of human thymidine kinase 2.

Authors:  Monica L Gerth; Stefan Lutz
Journal:  Biochem Biophys Res Commun       Date:  2007-01-23       Impact factor: 3.575

7.  Identification of residues involved in the specificity and regulation of the highly efficient multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster.

Authors:  W Knecht; B Munch-Petersen; J Piskur
Journal:  J Mol Biol       Date:  2000-08-25       Impact factor: 5.469

8.  Functional expression of a multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster and its C-terminal deletion mutants.

Authors:  B Munch-Petersen; W Knecht; C Lenz; L Søndergaard; J Piskur
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

9.  Kinetic properties of mutant deoxyguanosine kinase in a case of reversible hepatic mtDNA depletion.

Authors:  Bénédicte Mousson de Camaret; Jan-Willem Taanman; Sylvie Padet; Maïté Chassagne; Martine Mayençon; Pascale Clerc-Renaud; Ginette Mandon; Marie-Thérèse Zabot; Alain Lachaux; Dominique Bozon
Journal:  Biochem J       Date:  2007-03-01       Impact factor: 3.857

10.  Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.

Authors:  Lars Petter Jordheim; Carlos M Galmarini; Charles Dumontet
Journal:  Cancer Chemother Pharmacol       Date:  2006-02-04       Impact factor: 3.333

View more
  7 in total

Review 1.  Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

Authors:  Andressa Ardiani; Adam J Johnson; Hongmei Ruan; Marilyn Sanchez-Bonilla; Kinta Serve; Margaret E Black
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

2.  The phylogenetic distribution and evolution of enzymes within the thymidine kinase 2-like gene family in metazoa.

Authors:  Anke Konrad; Jason Lai; Zeeshan Mutahir; Jure Piškur; David A Liberles
Journal:  J Mol Evol       Date:  2014-02-06       Impact factor: 2.395

3.  Nonpolar nucleoside mimics as active substrates for human thymidine kinases.

Authors:  Sarah K Jarchow-Choy; Elena Sjuvarsson; Herman O Sintim; Staffan Eriksson; Eric T Kool
Journal:  J Am Chem Soc       Date:  2009-04-22       Impact factor: 15.419

4.  Biological phosphorylation of an Unnatural Base Pair (UBP) using a Drosophila melanogaster deoxynucleoside kinase (DmdNK) mutant.

Authors:  Fei Chen; Yuan Zhang; Ashley B Daugherty; Zunyi Yang; Ryan Shaw; Mengxing Dong; Stefan Lutz; Steven A Benner
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

5.  Engineering Kinases to Phosphorylate Nucleoside Analogs for Antiviral and Cancer Therapy.

Authors:  Stefan Lutz; Lingfeng Liu; Yichen Liu
Journal:  Chimia (Aarau)       Date:  2009-11-01       Impact factor: 1.509

6.  Directed evolution of an orthogonal nucleoside analog kinase via fluorescence-activated cell sorting.

Authors:  Lingfeng Liu; Yongfeng Li; Dennis Liotta; Stefan Lutz
Journal:  Nucleic Acids Res       Date:  2009-05-27       Impact factor: 16.971

Review 7.  Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future.

Authors:  María-Jesús Pérez-Pérez; Eva-María Priego; Ana-Isabel Hernández; Olga Familiar; María-José Camarasa; Ana Negri; Federico Gago; Jan Balzarini
Journal:  Med Res Rev       Date:  2008-09       Impact factor: 12.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.